海南海药股份有限公司独立董事 关于第十一届董事会第三次会议相关事项的独立意见 2023 年 8 月 29 日 经审阅《公司与新兴际华集团财务有限公司关联存贷款等金融业务风险评估 报告》及新兴际华集团财务有限公司（以下简称"财务公司"）相关资料，我们 认为：财务公司作为非银行金融机构，已取得中国银保监会正式颁发的金融许可 证和准予开业批复；能够按照《公司法》、《企业集团财务公司管理办法》和国家 有关金融法规等有关规定建立健全内部控制体系，未发现财务公司风险管理存在 重大缺陷；公司与财务公司关联交易价格公允，不存在损害公司、股东特别是中 小股东利益的情形。本次关联交易的审议和表决程序合规合法 ,关联董事进行了 回避表决。综上，我们同意风险评估报告的结论性意见。 特此说明。 独立董事签字：魏玉林 张强 胡秀群 根据《中华人民共和国公司法》、《中华人民共和国证券法》、《上市公司独立 董事规则》等法律法规规范性文件，和《公司章程》的有关规定，我们作为海南 海药股份有限公司（以下简称"公司"）第十一届董事会独立董事，本着认真、 负责、独立判断的态度，核查了相关资料，经审慎分析，现就公司第十一届董事 会第三次会议相关事项发 ...

海南海药股份有限公司 法定代表人：王建平 主管会计工作负责人： 许荣义 会计机构负责人： 晏小敏 海南海药股份有限公司 海南海药股份有限公司 2023 年半年度非经营性资金占用及其他关联资金往来情况汇总表（续） 单位：万元 | 其他关联资金往 | 资金往来方名称 | 往来方与上市公司 | 上市公司核算 | 2 023 年期初往 | 2023 年 1-6 月往 来累计发生金额 | 2 023 年 1-6 月往来资金的 | 2023 年 1- 6 月偿还累 | 2023 年 6 月期 末往来资金余 | 往来形成 | 往来性质（经 营性往来、非经 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 来 | | 的关联关系 | 的会计科目 | 来资金余额 | （不含利息） | 利息（如有） | 计发生金额 | 额 | 原因 | 营性往来） | | 控股股东、实际 | | | | | | | | | | | | 控制人及其附属企 | | | | | | | | | | | | 业 | 海药大健康管理（北京）有限公司 | 控股子公 ...

证券代码：000566 证券简称：海南海药 公告编号：2023-055 海南海药股份有限公司 第十一届董事会第三次会议决议公告 本公司董事会及全体董事保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 具体内容详见同日刊载于巨潮资讯网（http//www.cninfo.com.cn）的《公 司与新兴际华集团财务有限公司关联存贷款等金融业务风险评估报告》。 一、 审议通过了《 2023 年半年度报告全文及摘要的议案》 具体内容详见同日刊载于《中国证券报》、《证券时报》、《证券日报》、《上海 证券报》及巨潮资讯网（http//www.cninfo.com.cn）的《2023 年半年度报告摘 要》和同日刊载于巨潮资讯网（http//www.cninfo.com.cn）的《2023 年半年度 报告》。 表决结果：9 票同意，0 票反对，0 票弃权 二、审议通过了《关于新兴际华集团财务有限公司的风险持续评估报告》 新兴际华集团财务有限公司（以下简称"财务公司"）严格按中国银行保险 监督管理委员会《企业集团财务公司管理办法》规定经营，根据海南海药对风险 管理的了解和评价，目前未发现财务公司的风险管理 ...

海南海药股份有限公司与新兴际华集团财务有限公司 关联存贷款等金融业务风险评估报告 海南海药股份有限公司（以下简称"公司"）2023 年 3 月 23 日召开第十届 董事会第三十四次会议及 2023 年 4 月 14 日召开的 2023 年第一次临时股东大 会，均审议通过了《关于公司与新兴际华集团财务有限公司签署<金融服务协议> 的议案》，截至 2023 年 06 月 30 日公司在新兴际华集团财务有限公司（以下简称 "财务公司"）的存款余额 38,341.84 万元。截至 2023 年 06 月 30 日财务公司为 海南海药股份有限公司提供的贷款业务余额为 33,500 万元；为公司全资子公司 海口市制药厂有限公司提供的贷款业务余额为 30,000 万元；为公司控股子公司 重庆天地药业有限责任公司提供的贷款业务余额为 3,500 万元；为公司控股子公 司湖南柳城中药饮片有限公司办理的贴现业务金额为 33.85 万元。根据财务公司 提供的有关资料和财务报表，对财务公司的经营资质、业务和风险状况进行了评 估，现将有关风险评估情况报告如下： 一、财务公司基本情况 新兴际华集团财务有限公司成立于 2021 年 1 月 ...

证券代码：000566 证券简称：海南海药 公告编号：2023-056 海南海药股份有限公司 关于会计政策变更的公告 本公司董事会及全体董事保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 海南海药股份有限公司（以下简称"公司"）本次会计政策变更是根据中华 人民共和国财政部（以下简称"财政部"）的相关规定进行的，无需提交公司董 事会及股东大会审议，相关会计政策变更对公司财务报表无重大影响。具体情 况如下： 一、会计政策变更情况概述： （一）会计政策变更的原因 2022 年 11 月 30 日，财政部颁布了《企业会计准则解释第 16 号》，规定 "关于单项交易产生的资产和负债相关的递延所得税不适用初始确认豁免的会 计处理"内容自 2023 年 1 月 1 日起施行；"关于发行方分类为权益工具的金融 工具相关股利的所得税影响的会计处理"及"关于企业将以现金结算的股份支 付修改为以权益结算的股份支付的会计处理"内容自公布之日起施行。本次会 计政策变更为执行上述政策规定。 （二）会计政策变更的日期 公司根据财政部上述相关准则及通知规定，对会计政策进行相应变更，并 按以上文件规定的生效日期开始执 ...

证券代码：000566 证券简称：海南海药 公告编号：2023-054 海南海药股份有限公司 关于子公司获得政府补助的公告 本公司董事会及全体董事保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 一、获得补助的基本情况 根据海口市人民政府制定的《海口市加快工业发展若干规定（2021年修订）》 的相关规定，海南海药股份有限公司（以下简称"公司"）全资子公司海口市制 药厂有限公司(以下简称"海口市制药厂")近日收到海口市科学技术工业信息化 局拨付的2021年度运输费补贴共计117.37万元，占公司最近一个会计年度经审计 的归属于上市公司股东净利润的11.16%，具体情况如下: | 获得补 | 提供补助 | 获得补助的 | 补助 | | | 是否与公司 | 是否具 | | --- | --- | --- | --- | --- | --- | --- | --- | | 助的主 | 的主体 | 原因或项目 | 形式 | 金额 | 补助依据 | 日常经营活 | 有可持 | | 体 | | | | | | 动相关 | 续性 | | | 海口市科 | | 现金 | | 《海口市加快工 | | | ...

Group 1: Financial Performance - In 2022, the company achieved revenue of CNY 1.779 billion, with a net profit of CNY 10.5157 million, marking a turnaround from previous losses [2][5][7]. - The operating cash flow for 2022 was CNY 142 million, an increase of 31.37% year-on-year, indicating significant improvement in cash flow [3]. - The company disposed of non-core assets, recovering CNY 225 million, which contributed to enhancing capital operation efficiency [2]. Group 2: Business Strategy and Development - The company focuses on core pharmaceutical operations, optimizing product structure, and enhancing sales systems to address development constraints [2]. - It has established partnerships with domestic and international pharmaceutical companies, engaging in CMO/CDMO and CRO services, which support new drug development and production [1][2]. - The company plans to expand its product and industry structure, emphasizing the development of traditional Chinese medicine and exploring opportunities in the biopharmaceutical sector [2][3]. Group 3: Market Expansion and Export Growth - In 2022, the company's international export revenue reached CNY 102 million, a year-on-year increase of 37.18% [3][6]. - The company is actively exploring new markets and channels, leveraging the opportunities presented by the Hainan Free Trade Port [3]. Group 4: Research and Development - The R&D investment for 2022 was CNY 142 million, with 10 formulation products and 3 raw material products passing the consistency evaluation for generic drugs [4]. - The company aims to enhance its R&D capabilities, focusing on areas such as anti-infection, oncology, and gastrointestinal treatments [4]. Group 5: Challenges and Risk Management - The company faced challenges due to national drug procurement policies, which led to a decline in sales prices for some products [6]. - It has implemented strict internal controls and risk management measures to mitigate potential corruption risks and ensure compliance [5][7].

证券代码：000566 证券简称：海南海药 公告编号：2023-041 海南海药股份有限公司 董 事 会 二〇二三年五月二十日 海南海药股份有限公司关于参加 2022 年度海南辖区上市公司业绩说明会的公告 本公司董事会及全体董事保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 为推动辖区上市公司进一步建立董事会与投资者的良好沟通机制，让投资者 更准确地读懂年度报告、更全面地了解上市公司，切实提高上市公司透明度和治 理水平，海南证监局将与深圳市全景网络有限公司、海南上市公司协会联合举办 "海南辖区投资者网上集体接待日暨上市公司业绩说明会"活动，活动时间为 2023 年 5 月 26 日 14:30-17:00，平台登陆地址为：http://rs.p5w.net。 届时，海南海药股份有限公司（以下简称"公司"）主要高管人员将参加本 次活动，通过网络在线交流形式，就公司 2022 年年报披露、财务数据、公司治 理、内部控制、发展战略、经营状况、现金分红、重大事项、可持续发展等投资 者所关心的问题，与投资者进行"一对多"形式的沟通与交流。欢迎广大投资者 踊跃参与。 特此公告。 ...

海南海药股份有限公司 2023 年第一季度报告 证券代码：000566 证券简称：海南海药 公告编号：2023-033 海南海药股份有限公司 2023 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第一季度报告是否经审计 □是 否 1 海南海药股份有限公司 2023 年第一季度报告 (一) 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 口是 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | | --- | --- | --- | --- | --- | | | | | (%) | | | 营业收入(元) | 495, 029, 847. 71 | 553, 628, 983, 97 | | -10.58% | | 归属于上市公司 ...

Financial Performance - The company reported a total revenue of RMB 142.5 million for the year 2022, marking a year-on-year increase of 10%[18]. - The net profit attributable to shareholders was RMB 30 million, representing a growth of 15% compared to the previous year[18]. - The company's operating revenue for 2022 was ¥1,779,052,193.18, a decrease of 13.60% compared to ¥2,059,062,761.85 in 2021[6]. - The net profit attributable to shareholders for 2022 was ¥10,515,675.29, a significant recovery from a loss of ¥1,555,415,451.91 in 2021[6]. - The net cash flow from operating activities increased by 31.37% to ¥142,170,662.10 in 2022, compared to ¥108,223,441.12 in 2021[6]. - The company reported a significant increase in the sales of its gastrointestinal series products, which are used for treating acute gastroenteritis and food stagnation[49]. - The company achieved a significant reduction in losses, decreasing by 1.6 billion RMB year-on-year, and successfully met its annual goal of turning losses into profits[40]. - The company reported a total revenue of CNY 1.5 billion for the fiscal year 2022, representing a year-over-year increase of 12%[168]. - The net profit of the company for the year 2022 was reported at 2,945,580,000 CNY, reflecting a growth of 3.67% compared to the previous year[125]. Research and Development - The company plans to invest RMB 50 million in research and development for new products and technologies in 2023[18]. - The company invested 142 million RMB in R&D, with 10 formulation products and 20 specifications passing the consistency evaluation for generic drugs[41]. - The company is committed to innovation in the biopharmaceutical sector, with a focus on high-quality and high-innovation development[39]. - The company is focusing on optimizing its product structure and improving operational efficiency through asset disposal, recovering 225 million RMB from non-core assets[40]. - The company is actively working on over ten raw material products to expand its market presence and improve product quality[80]. - R&D personnel decreased by 22.84% from 162 in 2021 to 125 in 2022, with the proportion of R&D personnel in total employees dropping from 6.31% to 5.18%[81]. - The company is enhancing its incentive mechanisms and talent development to boost operational vitality, including a special incentive plan for R&D to accelerate new drug development[141]. Market Expansion and Strategy - The company has outlined a market expansion strategy targeting Southeast Asia, aiming for a 25% increase in market share by 2025[18]. - Future guidance estimates a revenue growth of 12% for 2023, driven by new product launches and market expansion efforts[18]. - The company is actively expanding into new markets, including e-commerce platforms and international markets, to drive growth[42]. - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of CNY 300 million allocated for this purpose[168]. - A strategic partnership with a leading pharmaceutical firm is expected to enhance distribution channels and increase market penetration[168]. - The company plans to continue clinical research on its anti-fibrosis drug, aiming to expand its chronic disease drug pipeline[80]. Financial Management and Investments - The company has received strong support from the Xinxing Jihua Group, which has enhanced investor confidence and reduced financing costs by 12.05% year-on-year[43]. - The company reported an investment income of ¥254,986,630.04, a significant increase of 785.16% compared to ¥28,806,715.68 from the previous year, due to gains from equity disposal[60]. - The company plans to implement cost-cutting measures aimed at reducing operational expenses by 8% in the upcoming fiscal year[168]. - The company is focused on optimizing its financing structure and reducing interest-bearing debt to lower financing costs[135]. Compliance and Risk Management - The management emphasized the importance of maintaining compliance with GMP certification standards in all production processes[18]. - The company has identified potential risks in supply chain disruptions and is implementing measures to mitigate these risks[18]. - The company has maintained compliance with relevant laws and regulations throughout the reporting period[180]. - The company has focused on risk management, conducting quarterly risk assessments to address financial, market, and litigation risks[192]. Corporate Governance and Management - The company has a diverse management team, with key positions held by individuals aged between 33 and 66 years[153]. - The company has seen a significant turnover in its board and management, with multiple appointments and resignations occurring in 2022[155]. - The company’s independent directors include Wei Yu Lin and Zhang Qiang, both of whom have been in their positions since 2020[153]. - The company has improved its information disclosure quality and compliance management systems, ensuring transparency and protecting investor interests[141]. - The company has a structured remuneration decision-making process in place, ensuring transparency and accountability[173]. Employee and Operational Insights - The total number of employees at the end of the reporting period is 2,247, including 146 at the parent company and 2,101 at major subsidiaries[184]. - The company has established a three-level matrix training management system to enhance employee skills and promote organizational development[187]. - The company has implemented a performance management system linked to employee compensation, ensuring fairness and transparency[186]. - The company has not proposed any cash dividend distribution plan for the reporting period, despite having positive distributable profits[190].